Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside - Archive ouverte HAL Access content directly
Journal Articles Autoimmunity Reviews Year : 2020

Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside

(1, 2) , (2) , (1, 3) , (1, 3) , (1) , (1, 2)
1
2
3

Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAVs) are small vessel vasculitides involving predominantly ear-nose-throat, kidneys, lungs and nerves. AAVs are life-threatening diseases, especially in their most severe forms such as necrotizing crescentic glomerulonephritis (GN) and/or intra-alveolar hemorrhage. Unlike immune complex GN or anti-glomerular basement membrane GN, AAVs are classified as pauci-immune GN. However, based on recent insights from animal models, the view of AAVs as a complement-unrelated disease has been challenged. Indeed, complement activation, and especially complement alternative pathway (cAP) activation, has been shown to be determinant in AAV pathogenesis through C5a generation, a potent chemoattractant for neutrophils with priming capacities. Here, we review in vitro and in vivo data supporting the role of cAP in murine models and in human AAVs. These findings, together with the need to eradicate glucocorticoid toxicity, led to the development of an anti-C5aR molecule, CCX168, also known as avacopan. Its development and future opportunities are also discussed.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02519542 , version 1 (26-03-2020)

Identifiers

Cite

Benoit Brilland, Anne-Sophie Garnier, Alain Chevailler, Pascale Jeannin, Jean-François Subra, et al.. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmunity Reviews, 2020, 19 (1), pp.102424. ⟨10.1016/j.autrev.2019.102424⟩. ⟨inserm-02519542⟩
36 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More